Muramyl dipeptide (
N-acetylmuramyl-L-alanyl-D-isoglutamine; AcMur-L-Ala-D-iGln; MDP) is a somnogenic, pyrogenic, and
immunoadjuvant component of bacterial cell wall
peptidoglycan. It enhances the production of the
cytokine interleukin 1 (IL-1) in vivo and in vitro;
IL-1 itself is somnogenic and pyrogenic. The pyrogenic effects of
IL-1 may be separated from its somnogenicity by the use of
antipyretics. A methyl
ester derivative of MDP (
murametide; AcMur-L-Ala-D-Gln-alpha-methyl
ester) blocks IL-1-induced
fever, but induces
IL-1 production/release. Therefore, the effects of
murametide on IL-1-induced sleep and
fever responses were determined. Rabbits were pretreated with
intravenous injections of
murametide 0, 30 or 60 min before
intravenous injection of a pyrogenic/somnogenic dose of recombinant
IL-1 beta (rIL-1 beta).
Murametide alone produced no effects on sleep or brain temperatures.
Murametide given simultaneously with rIL-1 beta potentiated increases of brain temperatures, whereas when there was a 60 min delay between the injection of
murametide and rIL-1 beta, responses were similar to those induced by rIL-1 beta alone.
Murametide given 30 min before rIL-1 beta, blocked the expected IL-1-induced
fevers but not the rIL-1 beta-mediated increases of slow-wave sleep and decreases of rapid-eye-movements sleep. These results reinforce the conclusion that, in part, independent brain mechanisms are involved in the somnogenic and pyrogenic actions of
IL-1.